文献速递血栓与止血

血浆纤溶酶原激活物抑制剂-1水平升高与未来发生静脉血栓栓塞症风险相关

Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2022-03-25

基于特罗姆瑟研究队列的巢式病例对照研究,纳入383例静脉血栓栓塞症(VTE)病例和782名年龄性别匹配对照,发现血浆纤溶酶原激活物抑制剂-1(PAI-1)抗原水平最高三分位组较低三分位组的VTE风险比值比为1.73(95%CI 1.27-2.35),且肥胖者中PAI-1介导了14.9%的VTE风险。

要点

  • PAI-1最高三分位组较低三分位组VTE风险比值比为1.73(95%CI 1.27-2.35)。
  • 逐步校正BMI和CRP后,风险估计仅轻度减弱。
  • 肥胖者中PAI-1介导14.9%(95%CI 4.1%-49.4%)的VTE风险。

核心结论

  • 血浆PAI-1水平升高与未来发生VTE风险增加相关,并可能部分介导肥胖者的VTE风险。

研究设计与样本

  • 基于特罗姆瑟研究队列的巢式病例对照研究,纳入383例VTE病例和782名年龄性别匹配对照。
  • 在队列纳入时采集的样本中测量PAI-1抗原水平,采用logistic回归计算VTE风险比值比(OR)及95%CI。

主要发现

  • 年龄和性别校正模型中,VTE风险随PAI-1三分位升高呈剂量依赖性增加(趋势P<.001)。
  • 最高三分位组较低三分位组VTE的OR为1.73(95%CI 1.27-2.35)。
  • 进一步校正BMI后OR为1.59(95%CI 1.16-2.17),再校正CRP后OR为1.54(95%CI 1.13-2.11)。
  • 对诱发性/非诱发性事件、深静脉血栓形成和肺栓塞获得相似结果。
  • 在肥胖者(BMI≥30 kg/m2对比<25 kg/m2)中,校正年龄、性别和CRP后PAI-1介导14.9%(95%CI 4.1%-49.4%)的VTE风险。

关键数值与推荐

  • PAI-1三分位分组:最高三分位组对比最低三分位组VTE的OR为1.73(95%CI 1.27-2.35)。
  • 肥胖定义为BMI≥30 kg/m2,对比BMI<25 kg/m2。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous thromboembolism (VTE) in obese subjects. However, whether PAI-1 is associated with VTE remains uncertain. OBJECTIVE: To investigate the association between plasma PAI-1 levels and risk of future incident VTE and whether PAI-1 could mediate the VTE risk in obesity. METHODS: A population-based nested case-control study, comprising 383 VTE cases and 782 age- and sex-matched controls, was derived from the Tromsø Study cohort. PAI-1 antigen levels were measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across PAI-1 tertiles. RESULTS: The VTE risk increased dose-dependently across PAI-1 tertiles (P for trend <.001) in the age- and sex-adjusted model. The OR of VTE for the highest versus lowest tertile was 1.73 (95% CI 1.27-2.35), and risk estimates were only slightly attenuated with additional stepwise adjustment for body mass index (BMI; OR 1.59, 95% CI 1.16-2.17) and C-reactive protein (CRP; OR 1.54, 95% CI 1.13-2.11). Similar results were obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism. In obese subjects (BMI of ≥30 kg/m2 vs. <25 kg/m2 ), PAI-1 mediated 14.9% (95% CI 4.1%-49.4%) of the VTE risk in analysis adjusted for age, sex, and CRP. CONCLUSION: Our findings indicate that plasma PAI-1 is associated with increased risk of future incident VTE and has the potential to partially mediate the VTE risk in obesity.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Frischmuth T, Hindberg K, Aukrust P, et al. Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. J Thromb Haemost. 2022. PMID: 35289062. doi:10.1111/jth.15701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。